Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) Sees Large Decrease in Short Interest

Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) was the recipient of a large drop in short interest during the month of September. As of September 15th, there was short interest totaling 267 shares, a drop of 93.5% from the August 31st total of 4,133 shares. Based on an average trading volume of 53,604 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the company’s shares are short sold.

Addex Therapeutics Price Performance

Shares of ADXN stock traded up $0.01 during mid-day trading on Thursday, hitting $3.46. The stock had a trading volume of 7,865 shares, compared to its average volume of 40,560. Addex Therapeutics has a 12-month low of $3.10 and a 12-month high of $11.97. The firm’s 50-day moving average is $4.67 and its two-hundred day moving average is $5.85. The firm has a market capitalization of $4.26 million, a P/E ratio of -0.58 and a beta of 1.47.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Addex Therapeutics in a research note on Monday, July 6th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

About Addex Therapeutics

Addex Therapeutics Ltd. (NASDAQ: ADXN) is a clinical-stage biopharmaceutical company headquartered in Geneva, Switzerland. The company develops small-molecule medicines that act through allosteric modulation, a drug-discovery approach designed to influence G protein-coupled receptors (GPCRs) at sites distinct from where naturally occurring signaling molecules bind.

Addex’s research has focused primarily on treatments for disorders of the central nervous system. Its development programs have included ADX71149, an investigational positive allosteric modulator of the metabotropic glutamate receptor 2 (mGluR2), and other compounds targeting neurological and psychiatric conditions.